Abstract
Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.
Keywords:
Alectinib; Anaplastic lymphoma kinase (ALK); Crizotinib; Esophageal ulceration; Non-small-cell lung cancer (NSCLC).
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Carbazoles / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / complications*
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Crizotinib
-
Endoscopes
-
Esophageal Diseases / chemically induced*
-
Esophageal Diseases / diagnosis
-
Female
-
Humans
-
Lung Neoplasms / complications*
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy*
-
Middle Aged
-
Piperidines / therapeutic use*
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrazoles / adverse effects*
-
Pyrazoles / therapeutic use
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
Ulcer / chemically induced*
-
Ulcer / diagnosis
Substances
-
Carbazoles
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Crizotinib
-
alectinib